This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2017 Jan-Feb;11(1-2):E62-E63.

doi: 10.5489/cuaj.4494. Epub 2017 Feb 20.

Supplementary data: Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer

Laurence Klotz¹, Rodney H Breau², Loretta L Collins³, Martin E Gleave⁴, Tom Pickles⁵, Frederic Pouliot⁶, Fred Saad⁷

Affiliations

Affiliations

¹ Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
² Ottawa Hospital Research Institute, Ottawa, ON, Canada.
³ Kaleidoscope Strategic, Toronto, ON, Canada.
⁴ Vancouver Prostate Centre, Vancouver, BC, Canada.
⁵ British Colombia Cancer Agency, Vancouver, BC, Canada.
⁶ Hôtel-Dieu de Québec, Quebec City, QC, Canada.
⁷ Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.

PMID: 28443152
PMCID: PMC5403685
DOI: 10.5489/cuaj.4494

Review

Supplementary data: Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer

Laurence Klotz et al. Can Urol Assoc J. 2017 Jan-Feb.

. 2017 Jan-Feb;11(1-2):E62-E63.

doi: 10.5489/cuaj.4494. Epub 2017 Feb 20.

Authors

Laurence Klotz¹, Rodney H Breau², Loretta L Collins³, Martin E Gleave⁴, Tom Pickles⁵, Frederic Pouliot⁶, Fred Saad⁷

Affiliations

¹ Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
² Ottawa Hospital Research Institute, Ottawa, ON, Canada.
³ Kaleidoscope Strategic, Toronto, ON, Canada.
⁴ Vancouver Prostate Centre, Vancouver, BC, Canada.
⁵ British Colombia Cancer Agency, Vancouver, BC, Canada.
⁶ Hôtel-Dieu de Québec, Quebec City, QC, Canada.
⁷ Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.

PMID: 28443152
PMCID: PMC5403685
DOI: 10.5489/cuaj.4494

No abstract available

PubMed Disclaimer

Similar articles

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.
Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Titus MA, et al. Clin Cancer Res. 2005 Jul 1;11(13):4653-7. doi: 10.1158/1078-0432.CCR-05-0525. Clin Cancer Res. 2005. PMID: 16000557
The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.
Shiota M, Fujimoto N, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M. Shiota M, et al. Prostate Cancer Prostatic Dis. 2016 Jun;19(2):191-6. doi: 10.1038/pcan.2016.2. Epub 2016 Feb 9. Prostate Cancer Prostatic Dis. 2016. PMID: 26857022
Variations in circulating sex steroid levels in metastatic prostate cancer patients with combined androgen blockade: observation and implication.
Qin X, Zhang H, Ye D, Yao X, Zhang S, Dai B. Qin X, et al. Andrology. 2013 May;1(3):512-6. doi: 10.1111/j.2047-2927.2013.00078.x. Epub 2013 Mar 28. Andrology. 2013. PMID: 23536478
Developments in the control of testicular function.
Swerdloff RS, Wang C, Bhasin S. Swerdloff RS, et al. Baillieres Clin Endocrinol Metab. 1992 Apr;6(2):451-83. doi: 10.1016/s0950-351x(05)80158-2. Baillieres Clin Endocrinol Metab. 1992. PMID: 1377467 Review.
Innovative approaches to the hormonal treatment of advanced prostate cancer.
Trachtenberg J. Trachtenberg J. Eur Urol. 1997;32 Suppl 3:78-80. Eur Urol. 1997. PMID: 9267790 Review.

See all similar articles

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations